Skip to main content
Business Breakdowns

Exor: Fiat Crisis to Ferrari Glory - [Business Breakdowns, EP.229]

48 min episode · 2 min read
·
Krishna Mohanaj

Episode

48 min

Read time

2 min

Topics

Productivity, Health & Wellness, Relationships

AI-Generated Summary

Key Takeaways

  • Ferrari value unlock: Exor sold €3 billion of Ferrari shares in February when the stake reached 50% of portfolio value, redeploying proceeds into share buybacks at 50-60% NAV discount and new investments in healthcare technology.
  • Decisive capital allocation: The company refreshes its asset mix two to three times annually, maintaining 20% debt-to-assets maximum while focusing on three sectors: healthcare technology, luxury goods, and artificial intelligence through strategic partnerships and board positions.
  • Healthcare strategy execution: Philips stake increased to 20% with board presence, combined with Institute BioMeru investment, positions Exor as legitimate health tech player. The sector offers secular growth in imaging, diagnostics, genomics, and medical services with patient capital advantage.
  • NAV growth measurement: Management benchmarks performance against MSCI World index using NAV per share growth as primary metric. Past performance driven entirely by Ferrari appreciation, while Stellantis, CNH, and Philips trade at undemanding multiples during cyclical troughs.

What It Covers

Exor operates as a Dutch holding company controlled by the Agnelli family, managing €45 billion across Ferrari, Stellantis, CNH, and Philips. The company trades at 50-60% discount to NAV despite systematic portfolio transformation.

Key Questions Answered

  • Ferrari value unlock: Exor sold €3 billion of Ferrari shares in February when the stake reached 50% of portfolio value, redeploying proceeds into share buybacks at 50-60% NAV discount and new investments in healthcare technology.
  • Decisive capital allocation: The company refreshes its asset mix two to three times annually, maintaining 20% debt-to-assets maximum while focusing on three sectors: healthcare technology, luxury goods, and artificial intelligence through strategic partnerships and board positions.
  • Healthcare strategy execution: Philips stake increased to 20% with board presence, combined with Institute BioMeru investment, positions Exor as legitimate health tech player. The sector offers secular growth in imaging, diagnostics, genomics, and medical services with patient capital advantage.
  • NAV growth measurement: Management benchmarks performance against MSCI World index using NAV per share growth as primary metric. Past performance driven entirely by Ferrari appreciation, while Stellantis, CNH, and Philips trade at undemanding multiples during cyclical troughs.

Notable Moment

At age 27, John Elkan inherited a failing Fiat facing bankruptcy with four CEOs in three years. His controversial decision to hire outsider Sergio Marchionne, who extracted $2 billion from General Motors, transformed the company from crisis to Chrysler merger.

Know someone who'd find this useful?

Episode Transcript

This is Business Breakdowns. Business Breakdowns is a series of conversations with investors and operators diving deep into a single business. For each business, we explore its history, its business model, its competitive advantages, and what makes it tick. We believe every business has lessons and secrets that investors and operators can learn from, and we are here to bring them to you. To find more episodes of breakdowns, check out joincolossus.com. All opinions expressed by hosts and podcast guests are solely their own opinions. Hosts, podcast guests, their employers, or affiliates may maintain positions in the securities discussed in this podcast. This podcast is for informational purposes only and should not be relied upon as a basis for investment decisions. I'm Zach Fuss. And today, we are breaking down Exor. The origins of Exor date back to the end of the nineteenth century when Giovanni Agnelli founded the auto company Fiat. In 1923, Exor acquired the Juventus Football Club, which it still owns today. But over the company's 100 year old history, a lot has changed. While some of the core assets remain the same, today, Exor serves as an investment holding company. Its largest and most notable assets are Ferrari, CNH, Stellantis, Phillips, and a number of other notable private companies. Additionally, they've shifted focus to bulking up their alternative asset management business, Sangato. Like many holding companies, XOR trades at a material discount to what the sum of its parts suggests. But management has been steadfastly working to close this discount by selling assets, reallocating capital, and repurchasing shares. Today, Exor is led by John Elkan, the grandson of the late Giovanni Agnelli, the founder of the Exor empire. Elkan was named heir of his grandfather at the age of 21 and has fostered and reshaped the business to what it is today. To break down Exor, I am joined by Krishna Mohanaj, a portfolio manager of the international strategy at Diamond Hill. We hope you enjoy this breakdown of XOR. Alright. Krishna, thanks for joining us once again this time to break down XOR, a business that has a storied history. Our listeners probably know a little bit about a lot of the parts of Exor, but I think bringing it all together today in this conversation to highlight the history of the business and what is in this family holding company will be really interesting. So just to kick things off, what is Exor? Zach, thank you. It's great to be back. Thanks for having me again. Exor is a fascinating business to talk about. It is a Dutch holding company controlled by the Agnelli family. Giovanni Agnelli was the founder of Fiat in the late eighteenth century, and their family wealth is managed through this holding company. It's a fascinating story for a couple of reasons. First, you've got the history. As you mentioned, Xor is a Dutch company on paper, but in its bones, it's all Italian. It's really the history of Fiat, …

Get the full transcript (8,305 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Business Breakdowns transcripts →

You just read a 3-minute summary of a 45-minute episode.

Get Business Breakdowns summarized like this every Monday — plus up to 2 more podcasts, free.

Pick Your Podcasts — Free

Keep Reading

More from Business Breakdowns

We summarize every new episode. Want them in your inbox?

Similar Episodes

Related episodes from other podcasts

Explore Related Topics

This podcast is featured in Best Business Podcasts (2026) — ranked and reviewed with AI summaries.

Read this week's Health & Longevity Podcast Insights — cross-podcast analysis updated weekly.

You're clearly into Business Breakdowns.

Every Monday, we deliver AI summaries of the latest episodes from Business Breakdowns and 192+ other podcasts. Free for one show.

Start My Monday Digest

No credit card · Unsubscribe anytime